WILMINGTON, Mass. & SHANGHAI, China--(BUSINESS WIRE)--Charles River Laboratories International, Inc.(NYSE: CRL) and WuXi PharmaTech (NYSE:WX) today announced that they have issued an updated investor presentation in connection with Charles River’s proposed acquisition of WuXi. The additional materials include the companies’ expectation that the combined company will generate at least $75 million to $100 million of revenue synergies on an annual basis by 2013. Investors may access the full presentation at Charles River’s website at www.criver.com/specialwuxi2010.